KURA Kura Oncology Inc.

-0.10  -1%
Previous Close 14.10
Open 14.15
Price To book 6.86
Market Cap 299245926
Shares 21,374,709
Volume 1,018,021
Short Ratio 0.89
Av. Daily Volume 951,816

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 first dosing announced January 17, 2016 with data due 1H 2018.
Chronic myelomonocytic leukemia (CMML) - cancer
Phase 2 data presented at ICML conference on June 14, 2017 - 3/18 partial responses.
Relapsed or refractory peripheral T-cell lymphoma
Phase 2 additional data due 2H 2017.
HRAS mutant solid tumors - cancer
Phase 2 top-line data due 1H 2018.
Lower risk myelodysplastic syndromes (MDS) - cancer

Latest News

  1. Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference
  2. Zacks.com featured highlights include Build-A-Bear Workshop, Kura Oncology, Norsk Hydro, Schnitzer Steel Industries and SYNNEX
  3. Is It Time To Buy Kura Oncology Inc (KURA)?
  4. 5 Stocks in Limelight on New Analyst Coverage
  5. Can Kura Oncology (KURA) Run Higher on Strong Earnings Estimate Revisions?
  6. Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data
  7. 3 Reasons Momentum Stock Investors Will Love Kura Oncology (KURA)
  8. Today's Research Reports on Stocks to Watch: Array BioPharma and Kura Oncology
  9. Kura Oncology Doubles on Mid-Stage Trial Results
  10. Stocks to Watch: Equifax, Pfizer, Kroger, Southwest, Kura Oncology, American Outdoor Brands
  11. Kura Oncology's stock rockets after positive results from cancer treatment trial
  12. Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer
  13. Kura Oncology to Participate in Citi’s 12th Annual Biotech Conference
  14. Kura Oncology Announces Pricing of Public Offering of Common Stock
  15. Kura Oncology Announces Commencement of Public Offering of Common Stock
  16. Kura Oncology reports 2Q loss
  17. Kura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 Study
  18. Investor Network: Kura Oncology, Inc. to Host Earnings Call
  19. Kura Oncology to Report Second Quarter 2017 Financial Results